GSTP1 DNA methylation and expression status is indicative of 5-aza-2′-deoxycytidine efficacy in human prostate cancer cells

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Chiam, Karen ^a,b   Centenera, Margaret M ^a   Butler, Lisa M ^a   Tilley, Wayne D ^a   Bianco Miotto, Tina ^a  

^a University of Adelaide   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA; GLUTATHIONE TRANSFERASE P1; ZEBULARINE; AZACITIDINE; CYTIDINE; DRUG DERIVATIVE; ENZYME INHIBITOR; GSTP1 PROTEIN, HUMAN; PROSTATE SPECIFIC ANTIGEN; PYRIMIDIN 2 ONE BETA RIBOFURANOSIDE; PYRIMIDIN-2-ONE BETA-RIBOFURANOSIDE; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; BLOOD; CELL DEATH; CELL SURVIVAL; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; MALE; PATHOLOGY; PROMOTER REGION; PROSTATE TUMOR; TIME; TUMOR CELL LINE;

AZACITIDINE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTIDINE; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; PROMOTER REGIONS, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053247020     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025634     Document Type: Article

References (60)

1. Huggins C, Stephens RC, Hodges CV, (1941) Studies on prostatic cancer: the effects of castration on advanced carcinoma of the prostate gland. Archives of Surgery 43: 209.
2. Jones PA, Taylor SM, (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20: 85-93.
3. Bender CM, Gonzalgo ML, Gonzales FA, Nguyen CT, Robertson KD, et al. (1999) Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol 19: 6690-6698.
4. Patra SK, Patra A, Dahiya R, (2001) Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 287: 705-713.
5. Patra SK, Patra A, Zhao H, Dahiya R, (2002) DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog 33: 163-171.
6. Perry AS, Foley R, Woodson K, Lawler M, (2006) The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr Relat Cancer 13: 357-377.
7. Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, et al. (2010) Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev 19: 2611-2622.
8. Brothman AR, Swanson G, Maxwell TM, Cui J, Murphy KJ, et al. (2005) Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer Genet Cytogenet 156: 31-36.
9. Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, et al. (2007) A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 67: 10657-10663.
10. Pulukuri SM, Rao JS, (2005) Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2′-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. Int J Oncol 26: 863-871.
11. Walton TJ, Li G, Seth R, McArdle SE, Bishop MC, et al. (2008) DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate 68: 210-222.
12. Nakayama T, Watanabe M, Suzuki H, Toyota M, Sekita N, et al. (2000) Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest 80: 1789-1796.
13. McCabe MT, Low JA, Daignault S, Imperiale MJ, Wojno KJ, et al. (2006) Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res 66: 385-392.
14. Zorn CS, Wojno KJ, McCabe MT, Kuefer R, Gschwend JE, et al. (2007) 5-aza-2′-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer. Clin Cancer Res 13: 2136-2143.
15. van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM, (1986) Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 46: 4831-4836.
16. Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, et al. (1998) A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 84: 87-89.
17. de Vos D, van Overveld W, (2005) Decitabine: a historical review of the development of an epigenetic drug. Ann Hematol 84 (Suppl 13): 3-8.
18. Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, et al. (2009) Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 15: 3881-3888.
19. Yoo CB, Cheng JC, Jones PA, (2004) Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans 32: 910-912.
20. Momparler RL, (2005) Pharmacology of 5-Aza-2′-deoxycytidine (decitabine). Semin Hematol 42: S9-16.
21. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, et al. (2006) Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24: 3984-3990.
22. Santourlidis S, Florl A, Ackermann R, Wirtz HC, Schulz WA, (1999) High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate 39: 166-174.
23. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, et al. (2006) Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 98: 255-261.
24. Singal R, van Wert J, Bashambu M, (2001) Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. Cancer Res 61: 4820-4826.
25. Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, et al. (2004) A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 10: 8472-8478.
26. Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, et al. (2007) Suberoylanilide hydoxamic acid (SAHA; vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 6: 51-60.
27. Tan LW, Bianco T, Dobrovic A, (2002) Variable promoter region CpG island methylation of the putative tumor suppressor gene Connexin 26 in breast cancer. Carcinogenesis 23: 231-236.
28. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB, (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93: 9821-9826.
29. Xiong Z, Laird PW, (1997) COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25: 2532-2534.
30. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, et al. (2003) Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95: 399-409.
31. Shang D, Liu Y, Liu Q, Zhang F, Feng L, et al. (2009) Synergy of 5-aza-2′-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and-independent prostate cancer cell lines. Cancer Lett 278: 82-87.
32. Festuccia C, Gravina GL, D'Alessandro AM, Millimaggi D, Di Rocco C, et al. (2008) Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells. Int J Oncol 33: 381-388.
33. Richter E, Masuda K, Cook C, Ehrich M, Tadese AY, et al. (2007) A role for DNA methylation in regulating the growth suppressor PMEPA1 gene in prostate cancer. Epigenetics 2: 100-109.
34. Bott SR, Arya M, Kirby RS, Williamson M, (2005) p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation. Prostate Cancer Prostatic Dis 8: 321-326.
35. Zhang Q, Rubenstein JN, Jang TL, Pins M, Javonovic B, et al. (2005) Insensitivity to transforming growth factor-beta results from promoter methylation of cognate receptors in human prostate cancer cells (LNCaP). Mol Endocrinol 19: 2390-2399.
36. Hurtubise A, Momparler RL, (2004) Evaluation of antineoplastic action of 5-aza-2′-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines. Anticancer Drugs 15: 161-167.
37. Steiner MS, Wang Y, Zhang Y, Zhang X, Lu Y, (2000) p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways. Oncogene 19: 1297-1306.
38. Xiong J, Epstein RJ, (2009) Growth inhibition of human cancer cells by 5-aza-2′-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status. Mol Cancer Ther 8: 779-785.
39. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, et al. (2009) The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23: 1019-1028.
40. Lubbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, et al. (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 114: 349-357.
41. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, et al. (2000) Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18: 956-962.
42. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, et al. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106: 1794-1803.
43. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, et al. (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103: 1635-1640.
44. Sorm F, Vesely J, (1968) Effect of 5-aza-2′-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma 15: 339-343.
45. Momparler RL, Momparler LF, Samson J, (1984) Comparison of the antileukemic activity of 5-AZA-2′-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk Res 8: 1043-1049.
46. Momparler RL, Rivard GE, Gyger M, (1985) Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia. Pharmacol Ther 30: 277-286.
47. Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, et al. (1981) Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 5: 453-462.
48. Bender CM, Pao MM, Jones PA, (1998) Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 58: 95-101.
49. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, et al. (2006) DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 66: 5495-5503.
50. Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, et al. (2007) Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 212: 330-344.
51. Karpf AR, Moore BC, Ririe TO, Jones DA, (2001) Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2′-deoxycytidine. Mol Pharmacol 59: 751-757.
52. Juttermann R, Li E, Jaenisch R, (1994) Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A 91: 11797-11801.
53. Ferguson AT, Vertino PM, Spitzner JR, Baylin SB, Muller MT, et al. (1997) Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2′deoxycytidine-induced cytotoxicity in human breast cancer cells. J Biol Chem 272: 32260-32266.
54. Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, et al. (2001) GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 159: 1815-1826.
55. Lin X, Asgari K, Putzi MJ, Gage WR, Yu X, et al. (2001) Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res 61: 8611-8616.
56. Xiang N, Zhao R, Song G, Zhong W, (2008) Selenite Reactivates Silenced Genes by Modifying DNA Methylation and Histones in Prostate Cancer Cells. Carcinogenesis.
57. Lemaire M, Momparler LF, Bernstein ML, Marquez VE, Momparler RL, (2005) Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia. Anticancer Drugs 16: 301-308.
58. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, et al. (2005) Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 11: 4037-4043.
59. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, et al. (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99: 167-170.
60. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, et al. (2009) The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 116: 53-68.